TLXTelix Pharmaceuticals Limited
What is the market doing?
No clear lean: nothing decisive, though insiders net buying.
Choppy, but holding above its 200-day average. Price is +17% vs its 200-day average.
Insiders were net buyers over the 90 days ending Oct 8, 2026.
A token position, settled Sep 15, 2026, a few days of normal trading to cover. Up 33% since the previous count, unchanged over three months.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How TLX is trading
Telix Pharmaceuticals Limited is +12% over the past year while the S&P 500 is +18%: 5.9 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +17%
vs 200-day average · a clear uptrend
- RSI (14)
- 49
RSI (14) · neutral
- Below its 52-week high
- 13%
Below its 52-week high
Details›
- Last close2026-10-09
- $11.22
- 1 monthS&P 500 +2.7%
- −5.7%
- 1 yearS&P 500 +18%
- +12%
- vs 50-day average$11.44
- −1.9%
- 52-week high
- $12.84
- 52-week low
- $6.41
- Annualised volatility
- 57%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $1.0M
| Year | Return |
|---|---|
| 2026 (year to date) | +50% |
| 2025 | −51% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry